A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

NCT06186076 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Carcinoma, Non-Small-Cell Lung
EGFR Mutant Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: TRX-221

Sponsor

Therapex Co., Ltd